Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,321 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02300610 | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | completed | Phase 1 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02333279 | Cancer Development In Organ Transplant Recipients | completed | — | 1,800 | University of ZurichOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02315755 | Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC | completed | — | 102 | PfizerINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT03744585 | Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.(CABOREAL) | completed | — | 450 | IpsenINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT00005851 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT01026337 | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | completed | — | 43 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT01206764 | A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. | completed | Phase 4 | 143 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 24, 2019 | clinicaltrials |
| NCT01415167 | PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy | completed | — | 1,690 | Prometheus LaboratoriesINDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT02729194 | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | completed | Early Phase 1 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT03887091 | Personal Web Page In Clinical Trial Participant Education | completed | N/A | 99 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00569946 | Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) | completed | Phase 2 | 64 | PfizerINDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT00853021 | Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney | completed | Phase 2 | 26 | Jorge A. Garcia, MDOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03514550 | Effects of Anesthesia on Immunity in Cancer | completed | Phase 4 | 20 | Meshalkin Research Institute of Pathology of CirculationNETWORK | 1 | Jun 3, 2019 | clinicaltrials |
| NCT01844947 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract(VINSOR) | completed | Phase 1 | 22 | Dr Anders UllénOTHER | 2 | Apr 26, 2019 | clinicaltrials |
| NCT02145559 | A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03427476 | CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma | completed | Phase 1 | 4 | Cancer Targeted TechnologyINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03064308 | The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery(POETold) | completed | N/A | 11 | University of NottinghamOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03556046 | 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE | completed | Phase 1 | 10 | Radboud University Medical CenterOTHER | 1 | Apr 1, 2019 | clinicaltrials |
| NCT02248389 | Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses(HIFU-KIDNEY) | completed | Phase 1 | 4 | Indiana UniversityOTHER | 1 | Mar 25, 2019 | clinicaltrials |
| NCT02454478 | Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | completed | Phase 1 | 7 | Eisai Co., Ltd.INDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00387205 | Study To Assess Long Term Safety Of Pazopanib | completed | Phase 1 | 188 | Novartis PharmaceuticalsINDUSTRY | 4 | Mar 6, 2019 | clinicaltrials |
| NCT01136733 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | completed | Phase 1 / Phase 2 | 173 | Eisai Inc.INDUSTRY | 5 | Feb 27, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01731158 | Sequential Therapy in Metastatic Renal Cell Carinoma(BERAT) | completed | Phase 2 | 22 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT02411968 | Follow up After Cryoablation of Small Renal Masses. | completed | — | 9 | Radboud University Medical CenterOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02585362 | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | completed | N/A | 52 | Kantonsspital Winterthur KSWOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01258348 | A Phase 1b Trial in Patients With Renal Cell Cancer | completed | Phase 1 | 21 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT01743469 | A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers | completed | Phase 2 | 201 | IpsenINDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT01538823 | Urine Proteome of Surgical Patients and Healthy Volunteers(UP) | completed | — | 664 | Washington University School of MedicineOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT03176485 | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | completed | N/A | 45 | University of ArizonaOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01688973 | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT00087022 | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | completed | Phase 3 | 864 | Heidelberg Pharma AGINDUSTRY | 4 | Nov 27, 2018 | clinicaltrials |
| NCT01762150 | Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma | completed | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01265368 | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)(ASET) | completed | Phase 1 / Phase 2 | 19 | Mologen AGINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 361 | National Cancer Institute (NCI)NIH | 2 | Nov 14, 2018 | clinicaltrials |
| NCT02966509 | Engagement of Patients With Advanced Cancer(EPAC) | completed | N/A | 213 | Stanford UniversityOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT01606787 | Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes | completed | Phase 3 | 210 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00606632 | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | completed | Phase 3 | 226 | Heidelberg Pharma AGINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02086734 | Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma | completed | — | 60 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT01158222 | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer | completed | Phase 2 | 37 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03670992 | Surgical Treatment of Pancreatic RCC Metastases | completed | — | 26 | Azienda Policlinico Umberto IOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01158521 | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01625936 | CRLX101 Plus Bevacizumab in Advanced RCC | completed | Phase 1 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2019source: clinicaltrials